Lerato Mohapi to Isoniazid
This is a "connection" page, showing publications Lerato Mohapi has written about Isoniazid.
Connection Strength
0,876
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
Score: 0,192
-
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 01; 31(1):17-27.
Score: 0,172
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 03 14; 380(11):1001-1011.
Score: 0,151
-
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016 Mar 19; 387(10024):1198-209.
Score: 0,123
-
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009 Mar 13; 23(5):631-6.
Score: 0,076
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
Score: 0,050
-
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Front Immunol. 2021; 12:676980.
Score: 0,044
-
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. BMC Pulm Med. 2019 Aug 14; 19(1):152.
Score: 0,039
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15; 61(8):1322-7.
Score: 0,029